Acquisition by Todd Harris of 1880 shares of Tyra Biosciences at 6.579 subject to Rule 16b-3
TYRA Stock | USD 14.00 0.50 3.45% |
About 55% of Tyra Biosciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Tyra Biosciences suggests that many traders are impartial. The current market sentiment, together with Tyra Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Tyra Biosciences stock news signals to limit their universe of possible portfolio assets.
Tyra |
Filed transaction by Tyra Biosciences Director, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Tyra Biosciences' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Tyra Biosciences' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Tyra Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tyra Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tyra Biosciences Fundamental Analysis
We analyze Tyra Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tyra Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tyra Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Tyra Biosciences is currently under evaluation in target price category among its peers.
Tyra Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tyra Biosciences stock to make a market-neutral strategy. Peer analysis of Tyra Biosciences could also be used in its relative valuation, which is a method of valuing Tyra Biosciences by comparing valuation metrics with similar companies.
Peers
Tyra Biosciences Related Equities
XLO | Xilio Development | 36.17 | ||||
GLUE | Monte Rosa | 6.45 | ||||
CGEM | Cullinan Oncology | 5.94 | ||||
IPSC | Century Therapeutics | 4.76 | ||||
DSGN | Design Therapeutics | 4.34 | ||||
MLYS | Mineralys Therapeutics, | 4.31 | ||||
ERAS | Erasca | 3.67 | ||||
STOK | Stoke Therapeutics | 3.36 | ||||
PHVS | Pharvaris | 2.95 | ||||
CCCC | C4 Therapeutics | 2.60 | ||||
RAPT | RAPT Therapeutics | 2.47 | ||||
HOWL | Werewolf Therapeutics | 1.27 | ||||
PMVP | Pmv Pharmaceuticals | 0.67 | ||||
EWTX | Edgewise Therapeutics | 0.06 | ||||
MOLN | Molecular Partners | 2.68 | ||||
IKNA | Ikena Oncology | 3.73 | ||||
CNTB | Connect Biopharma | 4.04 |
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |